Dr. Lee Michael Gerwitz, MD

Dr. Gerwitz practices at Renown Regional Medical Center in Reno, Nevada, part of Renown Health.

Dr. Gerwitz's NPI, 1972921591, was assigned on April 1, 2014. Dr. Gerwitz graduated from University of Rochester Medical Center in 2014. Dr. Gerwitz holds Nevada license 19680.

Dr. Gerwitz's primary practice is Renown Regional Medical Center, at 1155 Mill Street, Reno, NV 89502 in Washoe County. The practice phone is (775) 982-4100.

Dr. Gerwitz's primary practice is Renown Regional Medical Center in Reno, Nevada, part of Renown Health. Dr. Gerwitz is also affiliated with Renown South Meadows Medical Center. The medical group on file is Renown Health. Dmand AI also links Dr. Gerwitz to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gerwitz practices, 5 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Gerwitz's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Gerwitz is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Gerwitz's licenses on file in 3 states: Nevada, California and New York.

Dmand AI lists alzheimer's disease, carpal tunnel syndrome, epilepsy, fibromyalgia and chronic pain, lower back pain, migraine and chronic headache, multiple sclerosis and muscle weakness among the conditions Dr. Gerwitz treats.

CMS data shows 448 Medicare services from Dr. Gerwitz across 9 procedure codes in 2024, for 213 Medicare patients. Medicare paid $27,836 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 213 Medicare patients who saw Dr. Gerwitz in 2024. The largest group is 65 to 74, with 104 patients. 72% of them have high cholesterol, and 61% have high blood pressure. 18% are also on Medicaid. Their average risk score is 1.31, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gerwitz's median patient age at 65, with 75% women.

In 2024, Dr. Gerwitz wrote 896 Medicare Part D claims for 181 patients. 66% of them were for generic drugs. CMS names the drug for 656 of them, across 19 drugs with 11 or more claims each, at $762,043 in total drug cost. In 2023, CMS named 544 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Gerwitz for performance year 2024, reported as part of a group. Dr. Gerwitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gerwitz as offering telehealth.

Dmand AI links 2 papers to Dr. Gerwitz, published from 2019 to 2024. Dr. Gerwitz's most frequent co-authors are Bruce A. Cree, MD, Elizabeth George, MD and Carson Moseley, MD.

Dmand AI links Dr. Gerwitz to 1 clinical trial. 1 is still active or recruiting.

CMS Open Payments shows 385 general payments to Dr. Gerwitz from 21 drug and device companies from 2018 to 2025. Speaker and faculty fees make up the largest share, 49% of the total. EMD Serono, Inc. paid the most, $36,181. It also lists 9 research payments totaling $1,022 in 2018.

Dmand AI lists 3 awards for Dr. Gerwitz, most recently Department of Neurology Fellow Teaching Award in 2019.

Dr. Gerwitz graduated from University of Rochester Medical Center in 2014.

Dr. Gerwitz is in network with 6 carriers, including Aetna, United Healthcare and CMS Medicare. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.